Co-Irbecard 150/12,5 mg; 300/12,5 mg & 300/25 mg Tablets
PDF Leaflet Revision Date: 22 February 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of essential hypertension.
Dosage (summary)
One tablet daily; starting dose 150/12.5 mg, may increase to 300/12.5 mg as needed.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Potassium-sparing diuretics
- Lithium
- NSAIDs
Contraindications
- Hypersensitivity to components
- Severe renal impairment
- Pregnancy
- Lactation
Common side effects
- Dizziness
- Headache
- Nausea
- Fatigue
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Report any signs of allergic reactions
Serious warnings
- Hypotension in volume-depleted patients
- Risk of renal impairment
Important Disclaimer
The Co-Irbecard 150/12,5 mg; 300/12,5 mg & 300/25 mg Tablets professional information leaflet below is the property of Smart Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
